Ludwig researchers discover a targeted drug that overcomes suppressive immune cells, leading to improved responses to immune checkpoint blockade therapy in tumors with high concentrations of these cells. The findings offer a potential precision medicine approach for personalized treatment regimens.
A study by Ludwig Cancer Research identified a metabolic vulnerability in glioblastoma cells that can be exploited for therapy. GBM cells are extremely dependent on imported cholesterol and shutting down their import controls leads to dramatic cancer cell death and tumor shrinkage.
Researchers have developed a blood-based screening test to gauge colon cancer recurrence and monitor chemotherapy effects. The test detects tumor DNA fragments in the blood, which can identify patients at high risk of relapse and track treatment efficacy.
Scientists have identified 182 genome instability suppressing (GIS) genes in yeast and over 400 previously unknown cooperating GIS genes. These findings suggest a complex genetic network maintaining genome integrity and highlight potential therapeutic targets for cancer treatment.
A team of researchers has identified an alternate mechanism for evading therapy in brain cancer cells, which adapts within as little as three days of treatment. By targeting both the original and new signaling pathways, they can durably suppress tumor growth.
A Phase 1/2 clinical trial is being conducted to evaluate the combination of MedImmune's durvalumab and VentiRx's motolimod in locally advanced or recurrent ovarian cancers. The study aims to assess the safety and efficacy of the combination, with a focus on enhancing anti-tumor immune responses.
A new study published in Developmental Cell suggests that the KIF1Bβ gene plays a key role in determining whether neural crest cells live or die. The research team found that loss of KIF1B-β is associated with poor prognosis and reduced survival in neuroblastoma patients.
A team of researchers has mapped the connections between genetic mutations and protein regulation in glioblastoma multiforme (GBM) brain cancer. They found that targeting specific transcription factors, such as SOX9 and FOXG1, could potentially treat GBM using BET bromodomain inhibitors.
Researchers discovered that cancer cells incorporate chemically modified nucleosides into their DNA, which is toxic to them. The study found that modifying these nucleosides could be used as a specific anti-cancer agent, exploiting epigenetic changes in cancer cells.
Researchers found that glucose and acetate can activate key tumor signaling molecule mTORC2, allowing tumors to resist targeted therapies like EGFR inhibitors. This discovery provides a potential window into treating glioblastoma, a deadly brain cancer with limited treatment options.
Ludwig Cancer Research and the Cancer Research Institute launched clinical trials to evaluate immunotherapeutic strategies for brain cancer and various solid tumors. The trials will test MedImmune's checkpoint blockade antibody durvalumab in patients with glioblastoma multiforme, a deadly form of adult brain cancer.
A recent study by Ludwig Institute for Cancer Research has made a significant breakthrough in understanding the molecular mechanisms behind Parkinson's disease. The researchers discovered that disruption of a developmental mechanism, Lmx1b, leads to the death of dopamine-producing neurons, resulting in the symptoms of PD.
Researchers develop a novel approach to drug design using diabodies to tune cytokine receptor signaling. The method shows promise in targeting cancer cells and has the potential to reduce side effects by selectively blocking pathologic signals.
Two landmark studies reveal the interplay between chromosomal structure and gene expression across tissues. Researchers found that variations in gene expression are linked to differences in enhancer sequences and transcriptional regulation.
A new $10 million research program aims to investigate and experimentally validate nutritional interventions, develop reliable DNA tests, and introduce new cancer prevention strategies to the general public and policymakers. Research suggests that more than half of all colon cancers can be prevented through dietary and behavioral inter...
A team of researchers reveals that dendritic cells activate killer T cells through a protein named STING, which links DNA damage to interferon-β production. This suggests novel strategies for boosting radiotherapy effectiveness and combining it with immune system therapies.
Researchers have identified specific genetic mutations in melanoma tumors that predict effective responses to a groundbreaking immunotherapy. The discovery, published in the New England Journal of Medicine, could lead to more targeted and personalized cancer treatments, including tailored therapies for patients with diverse tumor genomes.
Ludwig researchers find ASPP2 acts as a molecular switch to regulate EMT and MET, crucial processes in cancer progression. Poor ASPP2 expression correlates with lower patient survival rates in liver and breast tumors.
A Ludwig Cancer Research study has identified a novel pathway by which proteins are actively and specifically shuttled into the nucleus. The discovery reveals a precise molecular barcode that flags proteins for import and describes the biochemical interaction driving this process.
Researchers found that injecting a virus directly into one melanoma tumor can induce a potent anti-tumor immune response, destroying both infected and non-infected tumors. This combination therapy overcomes the limitations of oncolytic virotherapy and checkpoint blockade.
A study by Ludwig Cancer Research uncovers a genomic phenomenon that explains why genetically identical animals are different in their biology and appearance. Single cell analysis reveals that one allele is expressed in between 12-24% of all pairs, with random switching throughout life.
Researchers discovered that glioblastoma (GBM) tumor cells hide the signaling molecule targeted by therapies, adding complexity to current models of drug resistance. The findings suggest alternative approaches that could improve outcomes for cancer patients and may have significant implications for therapeutic regimens.
Bing Ren has been awarded the distinction of Fellow by the American Association for the Advancement of Science (AAAS) for his outstanding contributions to genome-wide analysis and understanding of human disease. He is a member of the Ludwig Institute for Cancer Research and has directed various projects, including the Roadmap Epigenome...
A new technique called HaploSeq enables researchers to quickly determine which genetic variants occur together on the same chromosome and came from the same parent. This advance has direct implications for personalized medicine, improving organ donation matching and understanding human migration patterns.
Cancer cells use a process called the Warburg effect to extract energy from glucose, allowing them to sustain growth while retaining building blocks for molecules. Researchers identify a novel pathway involving mTORC2 that enables cancer cells to resist targeted therapies and develop new treatments.
A genetic variation that enhances p53's activity has been identified as a common mutation increasing the risk of testicular cancer in light-skinned individuals. This SNP, named KITLG p53 RE SNP, was positively selected in Caucasian gene pools due to its potential protective effect against UV radiation-induced skin damage.
A new technique for single-cell analysis of gene expression, named Smart-seq2, has been developed to identify rare cell subpopulations in tumors. This method captures three to four times as many RNA molecules as current methods, allowing for a more granular analysis of how subtle differences contribute to biology and disease.
A study found that the loss of CHD5 gene in stem cells underlies severe forms of neuroblastoma, a potentially curable tumor. CHD5 is required for cellular transition from a stem cell to a mature neuron, and its reactivation may increase responsiveness to treatment.
Researchers develop a therapeutic strategy that manipulates cellular heterogeneity to treat advanced melanoma. The approach uses a new drug-like molecule in combination with an existing chemotherapy, targeting only melanoma cells and suppressing tumor growth and metastasis.
A large research team elucidated how precise chemical modifications across the genome turn genes on and off during early human development. The study found that master genes governing development are silenced by histone methylation, while genes orchestrating cellular differentiation are primarily silenced by DNA methylation.
Scientists have discovered a mechanism to reactivate the tumor suppressor p53 in metastatic melanoma cells, which were previously silenced by proteins iASPP and MDM2. Treatment with a combination of small molecules JNJ-7706621 and Nutlin-3 restored p53 function and suppressed tumor growth in mice.
Researchers Arshad Desai and Christopher Campbell found that Aurora B kinase congregates on microtubules instead of the centromere, ensuring required tension is achieved on chromosomes. This discovery challenges prevailing model for how dividing cells monitor chromosome distribution.
Researchers developed prognostic biomarkers to determine melanoma patient benefit from new immunotherapy agents. Epigenetic regulators like microRNAs were found to inhibit metastasis and improve chemotherapy response in triple negative breast cancer.
Researchers identify a unique mechanism by which glioblastoma cells develop resistance to EGFR-targeting drugs by hijacking the signaling of PDGFRβ. Targeting both receptors simultaneously prevents resistance and suppresses tumors in laboratory models.
Three Ludwig scientists - Webster K. Cavenee, Bert Vogelstein, and Robert A. Weinberg - were named Fellows in the inaugural class of the AACR Academy for their pioneering work in cancer research. The recognition honors their contributions to enhancing cancer understanding and accelerating new treatments.
Researchers discovered a molecular mechanism that makes glioblastoma resistant to mTOR inhibitors, leading to the development of a new treatment approach. The novel combination therapy combines an mTOR inhibitor with low-dose arsenic to reverse resistance and induce tumor cell death.
A recent study found that the epigenetic marker 5-hydroxymethylcytosine (5hmC) plays a vital role in the selective expression of genes, particularly in healthy brain cells. The study also discovered that changes in 5hmC distribution are associated with gene silencing and may contribute to cancer development.
A mutation in a single amino acid on the thrombopoietin receptor alters its structure, causing permanent activation and leading to certain blood cancers. The tilted coils prevent spontaneous activation of the receptor.
Researchers identified microRNAs associated with oligometastatic progression, which differ from those associated with widespread metastatic disease. These findings suggest a biological basis for oligometastasis and potential use in identifying patients suitable for curative interventions.
Researchers have identified a novel type of T cell that can selectively target and destroy melanoma tumors. The discovery involves combining cyclophosphamide, an antibody that activates OX40 on T cells, with adoptive T cell transfer to eradicate advanced melanoma tumors in mice.
A recent study published in the Proceedings of the National Academy of Sciences reveals that a modification of the tumor suppressor gene PTEN is associated with resistance to glioblastoma treatments. The research suggests that targeting PTEN modification could lead to improved treatment outcomes for patients with glioblastoma.
Researchers at the Ludwig Institute for Cancer Research have discovered a molecular switch, ASPP2, that regulates autophagy and senescence in cells. Reduced levels of ASPP2 can lead to unchecked cell proliferation, promoting tumor growth.
A new genomic sequencing method called Smart-Seq has enabled the in-depth analysis of clinically relevant single cells. This breakthrough has significant implications for cancer research, allowing scientists to better understand tumor development and identify potential diagnostic markers.
Scientists from Ludwig Institute for Cancer Research (LICR) present promising research findings at ASCO. The studies aim to advance the scientific dialogue and potentially lead to new cancer treatments.
Researchers at Ludwig Institute for Cancer Research used powerful sequencing technology to investigate the three-dimensional structure of DNA folds in the nucleus. They found that DNA folds into local domains called topological domains, which are essential for gene regulation.
A study published in NEJM describes a rare case of the abscopal effect in a melanoma patient, where combining targeted radiation therapy with immunotherapy led to a strong immune response and favorable clinical outcome. The patient's pre-existing immunity to NY-ESO-1 antigen played a crucial role in the enhanced tumor regression.
Researchers found that combining chemotherapy with antibody treatment against intracellular antigens delays tumor growth and prolongs survival. The approach uses chemotherapy to release antigens from cancer cells, allowing antibodies to effectively target them.
Researchers have discovered a new target for cancer therapy, TDO enzyme, which enables tumors to evade immune rejection. A novel inhibitor of TDO has shown promising results in preclinical studies.
Researchers have successfully designed new IDO inhibitors using a docking algorithm, with 50% of in silico designs showing activity against human tumors. The computational tool, EADock, has shown promise for future drug developments in cancer-immunotherapy.
A study of nearly 1,600 tumor samples found that CT-X genes are expressed in half of ER-negative and triple-negative breast cancers. This suggests a potential new therapy approach for these aggressive breast cancer types. Researchers plan to initiate clinical trials based on the findings.